Abcam, ab300741, Anti-7-Methylguanosine antibody [EPR20846-92] (BSA and Azide free)

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal 7-Methylguanosine antibody. Carrier free. Suitable for Dot, FRET and reacts with Modified Nucleic Acid samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR20846-92,
Isotype:IgG,
Carrier free:Yes,
Applications:FRET, DotSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab300741 is the carrier-free version of
ab300740
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The target 7-Methylguanosine also known as 7-methylguanosine cap or 7-methylguanosine triphosphate (7-methylguanosine GTP) plays an important role in RNA processing. It is a modified nucleotide with a mass of approximately 362.3 Da. This cap structure is found at the 5' end of eukaryotic messenger RNA (mRNA). The 7-methylguanosine cap is expressed in the nucleus where it is added co-transcriptionally to nascent mRNA transcripts. This modification enhances mRNA stability and regulates its export to the cytoplasm.
Biological function summary
This cap modification promotes ribosomal binding facilitating efficient translation initiation. The 7-methylguanosine cap is part of the cap-binding complex which includes other proteins like eIF4E. This complex protects RNA from degradation and aids in splicing 5' end processing and polyadenylation. The methylation of the guanine base forms a structure that recruits proteins essential for mRNA maturation and function. Without this modification mRNA would display reduced translational efficiency and be more susceptible to exonucleolytic decay.
Pathways
7-methylguanosine participates in the RNA processing and translation initiation pathways. It interacts with the eukaryotic translation initiation factor 4E (eIF4E) a critical player in the regulation of mRNA cap-dependent translation. The binding of eIF4E to the 7-methylguanosine cap is essential for assembly of the eIF4F complex. This complex drives the mRNA to the ribosome facilitating protein synthesis. Additionally this cap structure influences mRNA export and poly(A) tail formation connecting to the broader mRNA metabolic pathway and impacting gene expression regulation.
Defects in the 7-methylguanosine cap can lead to improper mRNA processing and contribute to diseases like cancer and some congenital disorders. Dysregulation of cap-binding proteins such as eIF4E links to oncogenesis as these proteins can become overexpressed in cancers driving abnormal cell proliferation. Additionally cancer therapies often target these pathways to inhibit the translation of oncogenic mRNAs. Furthermore mutations or malfunctions in methylation enzymes can result in congenital developmental disorders as critical proteins necessary for normal growth and cellular function become deficient due to impaired mRNA translation.